30 research outputs found
Simon Says (Winter 2004)
Inside this issue: Library Patio NEH Preservation Assistance Grant netLibrary In Memoriam Rites of Passage Lectureshttps://csuepress.columbusstate.edu/library_newsletters/1004/thumbnail.jp
Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype
<p>Abstract</p> <p>Background</p> <p>Cystic fibrosis (CF) is caused by mutations in the <it>CFTR </it>gene that impair the function of CFTR, a cAMP-regulated anion channel. In the small intestine loss of CFTR function creates a dehydrated, acidic luminal environment which is believed to cause an accumulation of mucus, a phenotype characteristic of CF. CF mice have small intestinal bacterial overgrowth, an altered innate immune response, and impaired intestinal transit. We investigated whether lubiprostone, which can activate the CLC2 Cl<sup>- </sup>channel, would improve the intestinal phenotype in CF mice.</p> <p>Methods</p> <p><it>Cftr<sup>tm1UNC </sup></it>(CF) and wildtype (WT) littermate mice on the C57BL/6J background were used. Lubiprostone (10 μg/kg-day) was administered by gavage for two weeks. Mucus accumulation was estimated from crypt lumen widths in periodic acid-Schiff base, Alcian blue stained sections. Luminal bacterial load was measured by qPCR for the bacterial 16<it>S </it>gene. Gastric emptying and small intestinal transit in fasted mice were assessed using gavaged rhodamine dextran. Gene expression was evaluated by Affymetrix Mouse430 2.0 microarray and qRT-PCR.</p> <p>Results</p> <p>Crypt width in control CF mice was 700% that of WT mice (<it>P </it>< 0.001). Lubiprostone did not affect WT crypt width but, unexpectedly, increased CF crypt width 22% (<it>P </it>= 0.001). Lubiprostone increased bacterial load in WT mice to 490% of WT control levels (<it>P </it>= 0.008). Conversely, lubiprostone decreased bacterial overgrowth in CF mice by 60% (<it>P </it>= 0.005). Lubiprostone increased gastric emptying at 20 min postgavage in both WT (<it>P </it>< 0.001) and CF mice (<it>P </it>< 0.001). Lubiprostone enhanced small intestinal transit in WT mice (<it>P </it>= 0.024) but not in CF mice (<it>P </it>= 0.377). Among other innate immune markers, expression of mast cell genes was elevated 4-to 40-fold in the CF intestine as compared to WT, and lubiprostone treatment of CF mice decreased expression to WT control levels.</p> <p>Conclusions</p> <p>These results indicate that lubiprostone has some benefits for the CF intestinal phenotype, especially on bacterial overgrowth and the innate immune response. The unexpected observation of increased mucus accumulation in the crypts of lubiprostone-treated CF mice suggests the possibility that lubiprostone increases mucus secretion.</p
Mast Cells and Gastrointestinal Dysmotility in the Cystic Fibrosis Mouse
BACKGROUND: Cystic fibrosis (CF) has many effects on the gastrointestinal tract and a common problem in this disease is poor nutrition. In the CF mouse there is an innate immune response with a large influx of mast cells into the muscularis externa of the small intestine and gastrointestinal dysmotility. The aim of this study was to evaluate the potential role of mast cells in gastrointestinal dysmotility using the CF mouse (Cftr(tm1UNC), Cftr knockout). METHODOLOGY: Wild type (WT) and CF mice were treated for 3 weeks with mast cell stabilizing drugs (ketotifen, cromolyn, doxantrazole) or were treated acutely with a mast cell activator (compound 48/80). Gastrointestinal transit was measured using gavage of a fluorescent tracer. RESULTS: In CF mice gastric emptying at 20 min post-gavage did not differ from WT, but was significantly less than in WT at 90 min post-gavage. Gastric emptying was significantly increased in WT mice by doxantrazole, but none of the mast cell stabilizers had any significant effect on gastric emptying in CF mice. Mast cell activation significantly enhanced gastric emptying in WT mice but not in CF mice. Small intestinal transit was significantly less in CF mice as compared to WT. Of the mast cell stabilizers, only doxantrazole significantly affected small intestinal transit in WT mice and none had any effect in CF mice. Mast cell activation resulted in a small but significant increase in small intestinal transit in CF mice but not WT mice. CONCLUSIONS: The results indicate that mast cells are not involved in gastrointestinal dysmotility but their activation can stimulate small intestinal transit in cystic fibrosis
Fit to play: posture and seating position analysis with professional musicians - a study protocol
Expression of pro-Muclin in pancreatic AR42J cells induces functional regulated secretory granules
Transit of rhodamine dextran in the small intestine and effect of mast cell agents.
<p>Overnight fasted mice were gavaged with a bolus of rhodamine dextran (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0004283#s2" target="_blank">Methods</a>). At 20 min post-gavage the mice were sacrificed and the distribution of the fluorescence in 10 segments (proximal to distal) of the small intestine was measured and expressed relative to the total fluorescence. (A) WT Control (n = 28); (B) CF Control (n = 14); (C) Ketotifen, 3 week treatment of WT (n = 10); (D) Ketotifen, 3 week treatment of CF (n = 6); (E) Cromolyn, 3 week treatment of WT (n = 11); (F) Cromolyn, 3 week treatment of CF (n = 7); (G) Doxantrazole, 3 week treatment of WT (n = 5); (H) Doxantrazole, 3 week treatment of CF (n = 8); (I) Compound 48/80, acute i.p. injection of WT (n = 4); (J) Compound 48/80, acute i.p. injection of CF (n = 6). Data are means ± SEM. (*) <i>P</i><0.05 vs control, same genotype and same intestinal segment; (+) <i>P</i><0.05 CF vs WT, same segment and treatment group. Data for the control WT and CF mice include values from previous work <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0004283#pone.0004283-DeLisle1" target="_blank">[1]</a>.</p